We were delighted to catch up with Prof Daniel Kelly (Cardiff University, Wales, UK) to discuss the latest policy developments in the mission of HPV cancer elimination and the gender neutral vaccination plan.
1. How are the World Health Organisation and Europe’s Beating Cancer Plan working together to tackle HPV-associated cancers? (00:20-01:18)
2. What has been the impact of the HPV vaccine in terms of cancer prevention? (01:18-02:28)
3. What are the hopes for gender neutral vaccination? (02:28-03:38)
4. Could you tell us a little about the European Cancer Organisation’s HPV Action Network and its aims? (03:38-04:43)
5. How is the HPV Action Network working to improve gender neutral vaccination availability across Europe? (04:43-05:47)
Speaker Disclosure: Daniel Kelly has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Cancer Summit 2021
Share this Video
Related Videos In Policy
Raising awareness around HPV infection, cancer risk and vaccination: PrEvCan | Daniel Kelly
The PrEvCan – Cancer Prevention Across Europe – campaign, initiated by the European Oncology Nursing Society (EONS) and supported by ESMO, aims to reduce the burden of cancer by promoting a different way we can decrease cancer risk each month. This August, the PrEvCan campaign focuses on raising awareness about the connection between human papillomavirus […]
Vivek Subbiah, AACR 2023: The purpose of phase I clinical trials
The purpose of phase I clinical trials are to evaluate the safety, dosage and potential side effects of a new drug or treatment in humans for the first time. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) to discuss the purpose and details […]
Vivek Subbiah, AACR 2023: The evolution of phase I clinical trials in the era of precision medicine
Precision medicine aims to tailor medical treatments to individual patients based on their characteristics and genetic makeup. Phase I clinical trials are seeing changes in their objectives and designs in the era of precision medicine. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) […]